海洋放线菌素X2的抗肿瘤和抗病毒研究
|
摘要
目的
研究海洋放线菌素X2的生物学活性,主要是抗肿瘤和抗病毒活性的研究。
方法
1.利用MTT法检测不同浓度的海洋放线菌素X2对正常和肿瘤细胞的抑制作用;FCM测定海洋放线菌素X2对HepG-2细胞周期、细胞凋亡的改变;经Hoechst 33258(8g/L)染色进行形态学观察。
2.采用MTT法检测不同浓度的海洋放线菌素X2作用病毒后的抑制情况;采用RT-PCR和FCM分别测定CVB3诱导的ECV304细胞在海洋放线菌素X2作用前后不同时间点的ICAM-1和VCAM-1的mRNA和蛋白的表达水平;采用免疫细胞化学方法半定量分析CVB3诱导的ECV304细胞在海洋放线菌素X2作用前后不同时间点的NF-κB的活化情况。
结果
1、海洋放线菌素X2对多种肿瘤细胞都有抑制作用。在对HepG-2细胞增殖的研究中发现这种抑制作用具有时间-剂量依赖性,FCM检测发现HepG-2细胞细胞周期受到阻滞,停留于S期和G2/M期,细胞发生凋亡,荧光显微镜下观察发现HepG-2细胞中出现核固缩、凋亡小体。
2、海洋放线菌素X2在病毒吸附前对H1N1、CVB3的SI分别为47.66和63.88。
3.CVB3感染ECV304促进VCAM-1和的ICAM-1 mRNA表达,54h内表达均有增加,CVB3组、CVB3+X2组与对照组相比差异有显著性(P＜0.05).其中VCAM-1 mRNA表达在感染12h达到高峰,12h-24h表达量显著高于其他时间(P＜0.05);ICAM-1 mRNA表达在感染后显著增加(P＜0.05),24h-54h维持于高水平。海洋放线菌素X2干预后,分别于12-54h、24-54h降低VCAM-1和ICAM-1 mRNA的表达,与CVB3组相比差异有统计学意义(P＜0.05)。
4.CVB3感染ECV304,细胞表达VCAM-1和ICAM-1蛋白在12h-54h显著高于对照组(P＜0.05)。海洋放线菌素X2干预后,分别于12h-24h、12h-54h降低VCAM-1和ICAM-1蛋白的表达,与CVB3组相比差异有统计学意义(P＜0.05)。
5.免疫细胞化学方法和图像分析显示,ECV304经CVB3感染3h后NF-κB表达明显增强,活化入核细胞数增多,光密度值增加,与对照组相比较,差异有统计学意义(P＜0.05)。海洋放线菌素X2干预后,1h、3h时NF-κB的活化较CVB3组增强,而6h-24h时,NF-κB的活化受到明显抑制,表达下降。
结论
1.海洋放线菌素X2可抑制肿瘤细胞的增殖,均表现出时间-剂量依赖关系;阻滞HepG-2的细胞周期并可诱导其发生凋亡,形成凋亡小体。
2.海洋放线菌素X2在病毒吸附前对H1N1、CVB3具有抗病毒作用,
3.海洋放线菌素X2可能通过抑制NF-κB活化,下调CVB3诱导的ECV304细胞ICAM-1、VCAM-1的mRNA和蛋白表达。
OBJECTIVE
Study on the biologic activity of marine actinomycin X2.The main research is about anti-tumor and anti-viral.
METHODS
1.The inhibition of marine actinomyein X2 on normal and tumor cells proliferation was detected by MTT method.Flow cytometer was used to detect the change of HepG-2 cell cycle、apoptosis and those disposed cells were stained with Hoechst 33258(8g/L).
2.The inhibitory action of virus by use of different concentration marine actinomycin X2 by use MTT methods and study the effective of viral adsorption.Cytoplasmic RNA from ECV304 was extracted by the Trizol method and mRNA levels of ICAM-1, VCAM-1 were assayed by reverse transcript-polymerase chain reaction(RT-PCR) method respectively.Flow cytometer was used to detect the expression of ICAM-1, VCAM-1 on the infection ECV304 in different time courses respectively.Fluctuation of NF-κB was detected by semi-quantitative immunohistochemistry.
RESULTS
1.Marine actinomycin X2 has the inhibitory action to the tumor cells.FCM showed HepG-2 in G1 phase decreased,cells in S and G2/M phase increased,the cell cycle was arrested in S and G2/M phase.HepG-2 cell apoptosis with nuclear chromatin concentration and fragmentation as well as the formation of apoptotic bodies were observed.
2.Marine actinomycin X2 can inhibit virus before absorption of CVB3、H1N1 into the normal cells and SI weree 63.88,47.66.
3.The infection of CVB3 did promote the transcription of ICAM-1 and VCAM-1 in all 54h. The level of ICAM-1 and VCAM-1 mRNA in CVB3 group and CVB3+X2 group were higher than that of control group,and the differences had statistical significance(P＜0.05 ).The expression was increased in all 54h among which the VCAM-1 mRNA reached a peak at 12h point post-infection.There had expression of ICAM-1 mRNA in normal condition and increased after infection,especially between 24h-54h.In CVB3+X2 group at 12h-24h、12h-54h the expression of VCAM-1 and ICAM-1 mRNA was lower than CVB3 group(P＜0.05).
4.At the same time,we observed the significance increased expression VCAM-1 and ICAM-1 protein on the surface of ECV304 by the way of FCM at 12h-54h.In CVB3+X2 group at 12h-24h、12h-54h the expression of VCAM-1 and ICAM-1 protein was lower than CVB3 group(P＜0.05).
5.Our findings suggest that the level of NF-κB expression significantly increased in the CVB3 group aRer 3h.In CVB3+X2 group,at 1h、3h the level of NF-κB expression was increased,however,at 6h-24h the activation of NF-κB inhibited by X2.
CONCLUSION
1.Marine actinomycin X2 had significant inhibitory effect on tumor with dose and time-effect relationship.It arrested cell cycle、induced HepG-2 cells apoptosis and formed apoptosis bodies.
4.The mechanism of anti-virus of Marine actinomycin X2 possibly arrested the absorption of virus.
3.Marine actinomycin X2 decreased the expression of VCAM-1、ICAM-1 mRNA and protein maybe through inhibiting the activation of NF-κB.
研究海洋放线菌素X2的生物学活性,主要是抗肿瘤和抗病毒活性的研究。
方法
1.利用MTT法检测不同浓度的海洋放线菌素X2对正常和肿瘤细胞的抑制作用;FCM测定海洋放线菌素X2对HepG-2细胞周期、细胞凋亡的改变;经Hoechst 33258(8g/L)染色进行形态学观察。
2.采用MTT法检测不同浓度的海洋放线菌素X2作用病毒后的抑制情况;采用RT-PCR和FCM分别测定CVB3诱导的ECV304细胞在海洋放线菌素X2作用前后不同时间点的ICAM-1和VCAM-1的mRNA和蛋白的表达水平;采用免疫细胞化学方法半定量分析CVB3诱导的ECV304细胞在海洋放线菌素X2作用前后不同时间点的NF-κB的活化情况。
结果
1、海洋放线菌素X2对多种肿瘤细胞都有抑制作用。在对HepG-2细胞增殖的研究中发现这种抑制作用具有时间-剂量依赖性,FCM检测发现HepG-2细胞细胞周期受到阻滞,停留于S期和G2/M期,细胞发生凋亡,荧光显微镜下观察发现HepG-2细胞中出现核固缩、凋亡小体。
2、海洋放线菌素X2在病毒吸附前对H1N1、CVB3的SI分别为47.66和63.88。
3.CVB3感染ECV304促进VCAM-1和的ICAM-1 mRNA表达,54h内表达均有增加,CVB3组、CVB3+X2组与对照组相比差异有显著性(P＜0.05).其中VCAM-1 mRNA表达在感染12h达到高峰,12h-24h表达量显著高于其他时间(P＜0.05);ICAM-1 mRNA表达在感染后显著增加(P＜0.05),24h-54h维持于高水平。海洋放线菌素X2干预后,分别于12-54h、24-54h降低VCAM-1和ICAM-1 mRNA的表达,与CVB3组相比差异有统计学意义(P＜0.05)。
4.CVB3感染ECV304,细胞表达VCAM-1和ICAM-1蛋白在12h-54h显著高于对照组(P＜0.05)。海洋放线菌素X2干预后,分别于12h-24h、12h-54h降低VCAM-1和ICAM-1蛋白的表达,与CVB3组相比差异有统计学意义(P＜0.05)。
5.免疫细胞化学方法和图像分析显示,ECV304经CVB3感染3h后NF-κB表达明显增强,活化入核细胞数增多,光密度值增加,与对照组相比较,差异有统计学意义(P＜0.05)。海洋放线菌素X2干预后,1h、3h时NF-κB的活化较CVB3组增强,而6h-24h时,NF-κB的活化受到明显抑制,表达下降。
结论
1.海洋放线菌素X2可抑制肿瘤细胞的增殖,均表现出时间-剂量依赖关系;阻滞HepG-2的细胞周期并可诱导其发生凋亡,形成凋亡小体。
2.海洋放线菌素X2在病毒吸附前对H1N1、CVB3具有抗病毒作用,
3.海洋放线菌素X2可能通过抑制NF-κB活化,下调CVB3诱导的ECV304细胞ICAM-1、VCAM-1的mRNA和蛋白表达。
OBJECTIVE
Study on the biologic activity of marine actinomycin X2.The main research is about anti-tumor and anti-viral.
METHODS
1.The inhibition of marine actinomyein X2 on normal and tumor cells proliferation was detected by MTT method.Flow cytometer was used to detect the change of HepG-2 cell cycle、apoptosis and those disposed cells were stained with Hoechst 33258(8g/L).
2.The inhibitory action of virus by use of different concentration marine actinomycin X2 by use MTT methods and study the effective of viral adsorption.Cytoplasmic RNA from ECV304 was extracted by the Trizol method and mRNA levels of ICAM-1, VCAM-1 were assayed by reverse transcript-polymerase chain reaction(RT-PCR) method respectively.Flow cytometer was used to detect the expression of ICAM-1, VCAM-1 on the infection ECV304 in different time courses respectively.Fluctuation of NF-κB was detected by semi-quantitative immunohistochemistry.
RESULTS
1.Marine actinomycin X2 has the inhibitory action to the tumor cells.FCM showed HepG-2 in G1 phase decreased,cells in S and G2/M phase increased,the cell cycle was arrested in S and G2/M phase.HepG-2 cell apoptosis with nuclear chromatin concentration and fragmentation as well as the formation of apoptotic bodies were observed.
2.Marine actinomycin X2 can inhibit virus before absorption of CVB3、H1N1 into the normal cells and SI weree 63.88,47.66.
3.The infection of CVB3 did promote the transcription of ICAM-1 and VCAM-1 in all 54h. The level of ICAM-1 and VCAM-1 mRNA in CVB3 group and CVB3+X2 group were higher than that of control group,and the differences had statistical significance(P＜0.05 ).The expression was increased in all 54h among which the VCAM-1 mRNA reached a peak at 12h point post-infection.There had expression of ICAM-1 mRNA in normal condition and increased after infection,especially between 24h-54h.In CVB3+X2 group at 12h-24h、12h-54h the expression of VCAM-1 and ICAM-1 mRNA was lower than CVB3 group(P＜0.05).
4.At the same time,we observed the significance increased expression VCAM-1 and ICAM-1 protein on the surface of ECV304 by the way of FCM at 12h-54h.In CVB3+X2 group at 12h-24h、12h-54h the expression of VCAM-1 and ICAM-1 protein was lower than CVB3 group(P＜0.05).
5.Our findings suggest that the level of NF-κB expression significantly increased in the CVB3 group aRer 3h.In CVB3+X2 group,at 1h、3h the level of NF-κB expression was increased,however,at 6h-24h the activation of NF-κB inhibited by X2.
CONCLUSION
1.Marine actinomycin X2 had significant inhibitory effect on tumor with dose and time-effect relationship.It arrested cell cycle、induced HepG-2 cells apoptosis and formed apoptosis bodies.
4.The mechanism of anti-virus of Marine actinomycin X2 possibly arrested the absorption of virus.
3.Marine actinomycin X2 decreased the expression of VCAM-1、ICAM-1 mRNA and protein maybe through inhibiting the activation of NF-κB.
引文
[1]Malmstrom J,Christophersen C,Barrero A F,et al.Bioactive metabolites from a marine derived strain of the fungus Emedcella variecolor[J].J Nat Prod,2002,65(3):364-367.
[2]Canedo L M,Fernandez-Puentes J L,Baz J P.IB-96212,a novel cytotoxic macrolide produced by a marine Micromonospora.Ⅱ.Physico-chemical properties and structure determination[J].J Antibiot,2000,53(5):479-483.
[3]Zheng Z H,Zeng W,Huang Y J,et al.Detection of antitumor and antimicrobial activities in marine organism associated actinomycetes isolated from the Taiwan Strait,China[J].FEMS Microbiology Letters,2000,188(1):87-91.
[4]刘志鸿,程力,牟海津,等.海洋微生物活性物质的研究概况[J].中国水产科学,1999,6(4):99-103.
[5]M.Ballester,J.M.Ballester,J.P.Belaich,et al..Isolation and Characterization of a High Molecular Weight Antibiotic Produced by a Marine Bacterium[J].Microbial Ecology,1977,3(4):289-303.
[6]Yoshikawa K,Takadera T.Korormicin,a novel antibiotic specifically active against marine gram-negative bacteria,produced by a marine bacterium.[J].J Antibiot,1997,50(11):949-953.
[7]Strongman DB.A culmorin by marine fungi Leptosphaeda oraemaris[J].J Bot Mar,1986,30(1):21-25.
[8]陈碧娥,张思梨.海洋真菌Aspergillus sp.MF134的抗菌特性[J].华侨大学学报(自然科学版),2007,27(3):307-309.
[9]李淑彬,陆广欣,林如妹,等.具抗真菌活性的海洋霉菌的筛选和初步研究[J].微生物学通报,2005,32(2):78-82.
[10]Onuld H,Miyashige H and Hasegawa H,et al.NI15501A,a novel anthranilamide derivative from a marine fungus Penicil liumsp[J].J Antibiot 1998,51(4):442-444.
[11]Jadulco R,Brauers G,Edrada R A,et al.New metabolites from sponge-derived fungi Curvularia lunataand Claosporium herbarum[J].J Nat Prod.,2002,65(5):730-733.
[12]吴少杰,王淑军,李富超,等.胶州湾海洋放线菌的分布及其抗微生物活性[J].中国海洋药物,2006,25(5):10-13.
[13]Yang S W,Chan T M,Terracciano J,et al.A new anthracycline antibiotic micromonomycin from Micromonospora sp.[J].J Antibiot,2004,57(9):601-604.
[14]Furumai T,Igarashi Y,Higuchi H,et al.Kosinostatin,a quinoeycline antibiotic with antitumor activity from Micromonospora sp.TP-A0468[J].J Antibiot,2002,55(2):128-133.
[15]Fernandez-Chimeno R I,Romero F.IB-96212,a novel cytotoxicmacrolide produced by a marine micromonospora.I.Taxonomy,fermentation,isolation,and biological activities[J].J Antibiot,2000,53(5):474-478.
[16]黄耀坚,黄益丽,刘三震,等.具有免疫活性多糖海洋细菌菌株的筛选[J].台湾海峡,2004,23(1):38-42.
[17]Kalaitzis J A,Hamano Y,Nilsen G,et al.Biosynthesis and structural revision of neomarinone[J].Org Lett,2003,5(23):4449-4452.
[18]Malet-Cascon L,Romero F,Espliego-Vazquez F,et al.IB-00208,a new cyctotoxic polycyclic xanthone produced by a marine derived Actinomadura.I.Isolation of the strain,taxonomy and biological activities[J].J Antibiot,2003,56(3):219-225.
[19]Rodriguez J C,Puents J L F,Baz J P,et al.IB-00208,a new cyctotoxic polycyclic xanthone produced by a marine derived Actinomadura.Ⅱ.Isolation,physicochemical properties and structure determination[J].J Antibiot,2003,56(3):318-321.
[20]Amagata T,Minoura K,Numata A.Cytotoxic metabolites produced by a fungal strain from a Sargassum alga[J].J.Antibiot.,1998,51(4):432-434.
[21]王伯婧,冯雁,王师钰,等.嗜热酶的特性及其应用[J].微生物学报,2002,42(2):259-262.
[22]Sun- og L,Junichi K,Noboru T,et al.Involvement of anextracellular protease in algicidal activity of the marine bacterium Pseudoalteromonas sp.strain A28[J].Appl Envir Microbiol,2000,66(10):4334-4339.
[23]黄志强,林白雪,谢联辉,等.产碱性蛋白酶海洋细菌的筛选与鉴定[J].福建农林大学学报(自然科学版),2006,35(4):416-420.
[24]郝建华,孙谧,王跃军,等.海洋细菌QD80低温碱性蛋白酶的基因克隆和性质[J].中国生物化学与分子生物学报,2005,21(4):465-470.
[25]孙谧,王跃军,张云波,等.一株产低温碱性蛋白酶嗜冷海洋细菌YS-9412-130的分离和培养条件研究[J].海洋水产研究,2000,21(4):1-5.
[26]张绣,王跃军,孙谧,等.海洋细菌S-12-86的产溶菌酶条件[J].中国水产科学,2007,14(3):425-429.
[27]Dong J,Tamaru Y,Araki T,et al.A uniqueβ-agarase,AgaA,from a marine bacterium,Vibdo sp.strain PO-303[J].Appl Microbiol Biotechnol,2007,74(6):1248-1255.
[28]Hu X,Jiang X,Hwang HM,et al.Purification and Characterization of an Alginate Lyase from Marine Bacterium Vibrio sp.mutant strain 510-64[J].Cur Microbiol,2006,53(2):135-140.
[29]Woo JH,Hwang YO,Kang SG,et al.Cloning and characterization of three epoxide hydrolases from a marine bacterium,Erythrobacter litoralis HTCC2594[J].Appl Microbiol Biotechnol,2007,76(2):365-375.
[30]Simpson H,Denis M,Malatesta F,et al.The Terminal Oxidase in the Marine Bacterium Pseudomonas nautica 617[J].Bioscience Reports,1997,17(3):343-346.
[31]Ui H,Shiomi K,Yamaguchi Y,et al.Nafuredin,a novel inhibitor of NADH - fumarate reducetase produce by Aspergillus niger FT-0554[J].J.Antibiot.,2001,54(3):234-238.
[32]范延辉,胡江春,王书锦,等.海洋细菌B3B产河豚毒素特性的鉴定及其发酵培养基优化[J].应用与环境生物学报,2007,13(3):361-364.
[33]王黎,郑龙熙.富产多烯不饱和脂肪酸(PUFA)细菌的分离[J].东北大学学报(自然科学版),1999,20(5):529-532.
[34]Watanabe K,Ishikawa C,Ohtsuka I,et ai.Lipid and fatty acid compositions of a novel docosahexaenoic acidproducing marine bactedum[J].Lipids,1997,32(9):975-978.
[35]韩文君,路新枝,肖琳,等.一株产褐藻酸多糖的海洋假单胞细菌Pseudomonassp.QDA 的筛选和鉴定[J].中国海洋大学学报,2004,34(1):60-64.
[36]Schiano Modello V,Lama A,Poli A,et al.Production of exopolysaccharides from a thermophilic microorganism isolated from a marine hot spring in flegrean areas[J].J Ind Microbiol Biotechnol,2003,30(2):95-101.
[37]Tomshieh SV,Komandrova NA,Widmalm G,et al.Structure of acidic O-specific polysaccharide from the marine bacterium cellulophaga baltica[J].Russian Journal of Bioorganic Chemistry,2007,33(1):91-95.
[38]李厚金,蔡创华,周毅频,等.大亚湾海洋细菌Pseudomonas sp.中的红色素[J].中山大学学报(自然科学版),2003,42(3):102-104.
[39]温露,袁保红,李厚金,等.南海海洋细菌Pseudomonas sp.产生的一种抗肿瘤蓝色素[J].中山大学学报(自然科学版),2005,44(4):63-69.
[40]谷志静,陈锡时,韩士杰,等.海洋光合细菌Rx菌株的分离鉴定与生物学特性研究[J].西北农林科技大学学报(自然科学版),2004,32(9):47-52.
[41]王辂,褚以文.微生物来源先导化合物的研究策略[J].中国天然药物[J],2006,4(3):162-167.
[42]Bull AT,Ward AC,Goodfellow M.Search and discovery strategies for biotechnology:the paradigm shift.Mierobiol Mol Biol Rev[J],2000,64(3):573-606.
[43]Okami Y,Okazaki T,Kitahara T.Studies on marine microorganisms.V.A new antibiotic,aplasmomycin,produced by a streptomycete isolated from shallow sea mud[J].J Antibiot(Tokyo),1976,29(10):1019-1025.
[44]Ward AC,Bora N.Diversity and biogeography of marine actinobacteria[J].Curr Opin Microbiol,2006,9(3):279-286.
[45]Li F,Maskey R P,Qin S,et al.CH1N1komycins A and B:isolation,structure elucidation,and biological activity of novel antibiotics from a marine Streptomyces sp.isolate M045[J].J Nat Prod,2005,68(3):349-353.
[46]Maskey RP,Helmke E,KayserO,et al.Anti-cancer and antibacterial trioxacarcins with high anti-malaria activity from a marine Streptomycete and their absolute stereochemistry[J].J Antibiot(Tokyo),2004,57(12):771-779.
[47]XiongL,Li J,KongF.Streptomyces sp.173,an insecticidal microorganism from marine[J].Lett Appl Microbiol,2004,38(1):32-37.
[48]潘云娣,杨文鸽,候温甫,等.产杀虫活性物质海洋放线菌的筛选和初步鉴定[J].海洋通报,2006,25(4):92-96.
[49]刘妍,李志勇.具有多重酶活性的澳大利亚厚皮海绵共附生放线菌的研究[J].生物技术通报,2006,5:121-125.
[50]Imada C.Enzyme inhibitors and other bioactive compounds from marine actinomycetes[J].Antonie Van Leeuwenhoek,2005,87(1):59-63.
[51]赵俊凌,古静燕,候大斌,等.海洋放线菌抗肿瘤活性物质研究进展[J].海洋通报,2007,26(2):91-94.
[52]Bull AT,Stach J E,Ward A C,et al.Marine actinobacteria:perspectives,challenges,future directions[J].Antonie Van Leeuwenhoek,2005,87(3):65-79.
[53]Mincer TJ,Jensen PR,Kauffman CA,et al.Widespread and persistent populations of a major new marine actinomycete taxon in ocean sediments[J].Appl Environ Microbiol,2002,68(10):5005-5011.
[54]Sabry SA,Ghanem NB,Abu-Ella GA,et al.Noeardiopsis aegyptia sp.nov.,isolated from marine sediment[J].Int J Syst Evol Microbiol,2004,54(2):453-456.
[55]Magarvey NA,Keller JM,Beman V,et al.Isolation and characterization of novel marine-derived actinomycete taxa rich in bioactive metabolites[J].Appl Environ Microbiol,2004,70(12):7520-7529.
[56]Pathom-Aree W,Staeh J E,Ward AC,et al.Diversity of actinomycetes isolated from Challenger Deep sediment(10,898 m) from the Mariana Trench[J].Extremophiles,2006,10(3):181-189.
[57]姜健,范圣第,杨宝灵,等.海洋动植物共附生微生物的分离和抗菌活性研究[J].微生物学通报,2005,32(2):65-68.
[58]刘丽,胡江春,王书锦.繁茂膜海绵中两株放线菌的生物学特性及其鉴定[J].氨基酸和生物资源,2004,26(1):1-4.
[59]Zhang H,Lee YK,Zhang W,et al.Culturable actinobacteria from the marine sponge Hymeniacidon perleve:isolation and phylogenetic diversity by 16S rRNA gene-RFLP analysis[J].Antonie Van Leeuwenhoek,2006,90(2):159-169.
[60]Piel J,Hui D,Wen G,et al.Antitumor polyketide biosynthesis by an uncultivated bacterial symbiont of the marine sponge Theonella swinhoei[J].Proc Natl Acad Sci USA.2004,101(46):16222-16227.
[61]Hentschel U,Hopke J,Horn M,et al.Molecular evidence for a uniform microbial community in sponges from different oceans[J].Appl Environ Microbiol,2002,68(9):4431-4440.
[62]Kwon H C,Kauffman C A,Jensen P R,et al.Marinomycins A-D,antitumor-antibiotics of a new structure class from a marine actinomycete of the recently discovered genus "marinispora"[J].J Am Chem Soc,2006,128(5):1622-1632.
[63]Mincer T J,Fenical W,Jensen P R.Culture-dependent and culture-independent diversity within the obligate marine actinomycete genus Salinispora[J].Appl Environ Microbiol, 2005,71(11):7019-7028.
[64]Oh D C,Williams P G,Kauffman C A,et al.Cyanosporasides A and B,chloro-and cyano-cyclopenta[a]indene glycosides from the marine actinomycete "Salinispora pacifica"[J].Org Lett,2006,8(6):1021-1024.
[65]Kim T K,Hewavitharana A K,Shaw P N,et al.Discovery of a new source of rifamycin antibiotics in marine sponge actinobacteria by phylogenetic prediction[J].Appl Environ Microbiol,2006,72(3):2118-2125.
[66]Heald S C,Brandao P F,Hardiere R,et al.Physiology,biochemistry and taxonomy of deep-sea nitrile metabolising Rhodococcus strains[J].Antonie Van Leeuwenhoek,2001,80(2):169-183.
[67]Bruns A,Philipp H,Cypionka H,et al.Aeromicrobium marinum sp.nov.,an abundant pelagic bacterium isolated from the German Wadden Sea[J].Int J Syst Evol Microbiol,2003,53(Pt 6):1917-1923.
[68]Han S K,Nadashkovskaya O I,Mikhailov VV,et al.Salinibacterium amurskyense gen.nov.,sp.nov.,a novel genus of the family Microbacteriaceae from the marine environment[J].Int J Syst Evol Microbiol,2003,53(Pt 6):2061-2066.
[69]Fiedler HP,Bruntner C,Bull AT,et al.Marine actinomycetes as a source of novel secondary metabolites[J].Antonie Van Leeuwenhoek,2005,87(1):37-42.
[70]Jose M,Lopez S,Jensen PR,et al.New Cytotoxic Indolic Metabolites from a Marine Streptomyces[J].J Nat Prod,2003,66:863-864.
[71]王健,崔承彬,顾谦群,等.海洋来源黄直丝链霉菌产物中新细胞周期抑制剂的研究[J].中国海洋药物杂志,2005,24(4):1-5.
[72]Fenical W,Jensen PR.Developing a new resource for drug discovery:marine actinomycete bacteria[J].Nature Chemical Biology,2006,2(12):666-673.
[73]Fururnai T,Iqarashi Y.Kosinostatin,a quinocycline antibiotic with antitumor activity from Micromonosporasp.TP-A0468[J].Antibiotics,2002,55(2):128-133.
[74]Charan RD,Schlingmann G,Janso J,et al.Diazepinomicin,a new antimierobial alkaloid from marine Micromonospora sp.[J].J Nat Prod,2004,67(8):1431-1433.
[75]Maldonado LA,Fenical W,Jensen PR,et al.Salinispora arenicolagen nov,sp nov andSalinispora tropicasp nov,obligate marine actinomycetes belonging to the family Micromonosporaceae[J].Int J Syst Evol Microbiol,2005,55(pt 5):1759-1766.
[76]程元荣,郑卫.小单孢菌及其产生的次级生物活性代谢产物[J].中国抗生素杂志,2006,31(6):321-327.
[77]江红,林如,郑卫,等.海洋青铜小单孢菌FIM 02-523产生的脂肽类化合物FW523的分离鉴别和生物学活性[J].中国抗生素杂志,2006,31(5):267-271.
[78]Lik T,Brian LM,William HG;Lyngbouilloside,a Novel Glycosidic Macrolide from the Marine Cyanobacterium Lyngbya bouillonii[J].J Nat Prod,2002,65(6):925-928.
[79]Hanshan W,Su L,Jun X,et al.Isolation of Streptonigrin and Its Novel Derivative from Micromonospora as Inducing Agents of p53-Dependent Cell Apoptosis[J].J Nat Prod,2002,65(5):721-724.
[80]刘睿,朱天骄,朱伟明,等.海洋放线菌S1001中抗肿瘤活性成分的研究[J].中国抗生素杂志,2006,31(1):36-38.
[81]刘妍,李志勇.海洋放线菌研究的新进展[J].生物技术通报.2005,6:34-39.
[82]Ho-shik K,Rhim H,Jenong SW,etal.Induction of apoptosis dependent on caspase activities and growth arrest in HL-60 cells by PGA2[J].Prostaglandins Other Lipid Mediat,2002,70(1):169-183.
[83]曾益新.肿瘤学[M].北京:人民卫生出版社.2003,83-85,109-110,151-176,209-224.
[84]周彩虹,黄启福.凋亡与肿瘤及其治疗进展[J].中国病理生理杂志,2004,20(11):2124-2133.
[85]Damia G,Broggini M.Improving the selectivity of cancer treatments by interfering with cell response pathways[J].Eur J Cancer,2004,40(17):2550-2559.
[86]Muckelbauer JK,Kremer M,Minor I,et al.The structure of coxsackievirus B3 at 3.5 A resolution[J].Structure.1995,3(7):653-667.
[87]Carson SD,Receptor for the group B coxsackieviruses and adenoviruses:CAR[J].Rev Med Virol,2001,11(4):219-226.
[88]Javett SN,Heymarm S,Mundel B,et al.Myocarditis in the new newborn infant;a study of an outbreak associated with Coxsackie group B virus infection in maternity home in Johannesburg[J].J Pediatr,1956,48(1):1-22.
[89]Saijets S,Ylipaasto P,Vaarala O,et al.Enterovirus infection and activation of human umbilical vein endothelial cells[J].J Med Virol,2003,70(3):430-439.
[90]Storz P,Toker A.NF-κB signaling-an alternate pathway for oxidative stress responses [J].Cell Cycle.2003,2(1):9-10.
[91]Shao J,Fujiwara a,Kadowaki Y,et al.Overexpression of the wild-typep53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells[J].Oncogene.2000,19(6):726-736.
[92]Sarkar FH,Li Y.NF-kappaB:a potential target for cancer chemoprevention and therapy[J].Front Biosci.2008,13:2950-2959.
[93]Van Waes C.Nuclear factor-kappaB in development,prevention,and therapy of cancer[J].Clin Cancer Res.2007,13(4):1076-1082.
[2]Canedo L M,Fernandez-Puentes J L,Baz J P.IB-96212,a novel cytotoxic macrolide produced by a marine Micromonospora.Ⅱ.Physico-chemical properties and structure determination[J].J Antibiot,2000,53(5):479-483.
[3]Zheng Z H,Zeng W,Huang Y J,et al.Detection of antitumor and antimicrobial activities in marine organism associated actinomycetes isolated from the Taiwan Strait,China[J].FEMS Microbiology Letters,2000,188(1):87-91.
[4]刘志鸿,程力,牟海津,等.海洋微生物活性物质的研究概况[J].中国水产科学,1999,6(4):99-103.
[5]M.Ballester,J.M.Ballester,J.P.Belaich,et al..Isolation and Characterization of a High Molecular Weight Antibiotic Produced by a Marine Bacterium[J].Microbial Ecology,1977,3(4):289-303.
[6]Yoshikawa K,Takadera T.Korormicin,a novel antibiotic specifically active against marine gram-negative bacteria,produced by a marine bacterium.[J].J Antibiot,1997,50(11):949-953.
[7]Strongman DB.A culmorin by marine fungi Leptosphaeda oraemaris[J].J Bot Mar,1986,30(1):21-25.
[8]陈碧娥,张思梨.海洋真菌Aspergillus sp.MF134的抗菌特性[J].华侨大学学报(自然科学版),2007,27(3):307-309.
[9]李淑彬,陆广欣,林如妹,等.具抗真菌活性的海洋霉菌的筛选和初步研究[J].微生物学通报,2005,32(2):78-82.
[10]Onuld H,Miyashige H and Hasegawa H,et al.NI15501A,a novel anthranilamide derivative from a marine fungus Penicil liumsp[J].J Antibiot 1998,51(4):442-444.
[11]Jadulco R,Brauers G,Edrada R A,et al.New metabolites from sponge-derived fungi Curvularia lunataand Claosporium herbarum[J].J Nat Prod.,2002,65(5):730-733.
[12]吴少杰,王淑军,李富超,等.胶州湾海洋放线菌的分布及其抗微生物活性[J].中国海洋药物,2006,25(5):10-13.
[13]Yang S W,Chan T M,Terracciano J,et al.A new anthracycline antibiotic micromonomycin from Micromonospora sp.[J].J Antibiot,2004,57(9):601-604.
[14]Furumai T,Igarashi Y,Higuchi H,et al.Kosinostatin,a quinoeycline antibiotic with antitumor activity from Micromonospora sp.TP-A0468[J].J Antibiot,2002,55(2):128-133.
[15]Fernandez-Chimeno R I,Romero F.IB-96212,a novel cytotoxicmacrolide produced by a marine micromonospora.I.Taxonomy,fermentation,isolation,and biological activities[J].J Antibiot,2000,53(5):474-478.
[16]黄耀坚,黄益丽,刘三震,等.具有免疫活性多糖海洋细菌菌株的筛选[J].台湾海峡,2004,23(1):38-42.
[17]Kalaitzis J A,Hamano Y,Nilsen G,et al.Biosynthesis and structural revision of neomarinone[J].Org Lett,2003,5(23):4449-4452.
[18]Malet-Cascon L,Romero F,Espliego-Vazquez F,et al.IB-00208,a new cyctotoxic polycyclic xanthone produced by a marine derived Actinomadura.I.Isolation of the strain,taxonomy and biological activities[J].J Antibiot,2003,56(3):219-225.
[19]Rodriguez J C,Puents J L F,Baz J P,et al.IB-00208,a new cyctotoxic polycyclic xanthone produced by a marine derived Actinomadura.Ⅱ.Isolation,physicochemical properties and structure determination[J].J Antibiot,2003,56(3):318-321.
[20]Amagata T,Minoura K,Numata A.Cytotoxic metabolites produced by a fungal strain from a Sargassum alga[J].J.Antibiot.,1998,51(4):432-434.
[21]王伯婧,冯雁,王师钰,等.嗜热酶的特性及其应用[J].微生物学报,2002,42(2):259-262.
[22]Sun- og L,Junichi K,Noboru T,et al.Involvement of anextracellular protease in algicidal activity of the marine bacterium Pseudoalteromonas sp.strain A28[J].Appl Envir Microbiol,2000,66(10):4334-4339.
[23]黄志强,林白雪,谢联辉,等.产碱性蛋白酶海洋细菌的筛选与鉴定[J].福建农林大学学报(自然科学版),2006,35(4):416-420.
[24]郝建华,孙谧,王跃军,等.海洋细菌QD80低温碱性蛋白酶的基因克隆和性质[J].中国生物化学与分子生物学报,2005,21(4):465-470.
[25]孙谧,王跃军,张云波,等.一株产低温碱性蛋白酶嗜冷海洋细菌YS-9412-130的分离和培养条件研究[J].海洋水产研究,2000,21(4):1-5.
[26]张绣,王跃军,孙谧,等.海洋细菌S-12-86的产溶菌酶条件[J].中国水产科学,2007,14(3):425-429.
[27]Dong J,Tamaru Y,Araki T,et al.A uniqueβ-agarase,AgaA,from a marine bacterium,Vibdo sp.strain PO-303[J].Appl Microbiol Biotechnol,2007,74(6):1248-1255.
[28]Hu X,Jiang X,Hwang HM,et al.Purification and Characterization of an Alginate Lyase from Marine Bacterium Vibrio sp.mutant strain 510-64[J].Cur Microbiol,2006,53(2):135-140.
[29]Woo JH,Hwang YO,Kang SG,et al.Cloning and characterization of three epoxide hydrolases from a marine bacterium,Erythrobacter litoralis HTCC2594[J].Appl Microbiol Biotechnol,2007,76(2):365-375.
[30]Simpson H,Denis M,Malatesta F,et al.The Terminal Oxidase in the Marine Bacterium Pseudomonas nautica 617[J].Bioscience Reports,1997,17(3):343-346.
[31]Ui H,Shiomi K,Yamaguchi Y,et al.Nafuredin,a novel inhibitor of NADH - fumarate reducetase produce by Aspergillus niger FT-0554[J].J.Antibiot.,2001,54(3):234-238.
[32]范延辉,胡江春,王书锦,等.海洋细菌B3B产河豚毒素特性的鉴定及其发酵培养基优化[J].应用与环境生物学报,2007,13(3):361-364.
[33]王黎,郑龙熙.富产多烯不饱和脂肪酸(PUFA)细菌的分离[J].东北大学学报(自然科学版),1999,20(5):529-532.
[34]Watanabe K,Ishikawa C,Ohtsuka I,et ai.Lipid and fatty acid compositions of a novel docosahexaenoic acidproducing marine bactedum[J].Lipids,1997,32(9):975-978.
[35]韩文君,路新枝,肖琳,等.一株产褐藻酸多糖的海洋假单胞细菌Pseudomonassp.QDA 的筛选和鉴定[J].中国海洋大学学报,2004,34(1):60-64.
[36]Schiano Modello V,Lama A,Poli A,et al.Production of exopolysaccharides from a thermophilic microorganism isolated from a marine hot spring in flegrean areas[J].J Ind Microbiol Biotechnol,2003,30(2):95-101.
[37]Tomshieh SV,Komandrova NA,Widmalm G,et al.Structure of acidic O-specific polysaccharide from the marine bacterium cellulophaga baltica[J].Russian Journal of Bioorganic Chemistry,2007,33(1):91-95.
[38]李厚金,蔡创华,周毅频,等.大亚湾海洋细菌Pseudomonas sp.中的红色素[J].中山大学学报(自然科学版),2003,42(3):102-104.
[39]温露,袁保红,李厚金,等.南海海洋细菌Pseudomonas sp.产生的一种抗肿瘤蓝色素[J].中山大学学报(自然科学版),2005,44(4):63-69.
[40]谷志静,陈锡时,韩士杰,等.海洋光合细菌Rx菌株的分离鉴定与生物学特性研究[J].西北农林科技大学学报(自然科学版),2004,32(9):47-52.
[41]王辂,褚以文.微生物来源先导化合物的研究策略[J].中国天然药物[J],2006,4(3):162-167.
[42]Bull AT,Ward AC,Goodfellow M.Search and discovery strategies for biotechnology:the paradigm shift.Mierobiol Mol Biol Rev[J],2000,64(3):573-606.
[43]Okami Y,Okazaki T,Kitahara T.Studies on marine microorganisms.V.A new antibiotic,aplasmomycin,produced by a streptomycete isolated from shallow sea mud[J].J Antibiot(Tokyo),1976,29(10):1019-1025.
[44]Ward AC,Bora N.Diversity and biogeography of marine actinobacteria[J].Curr Opin Microbiol,2006,9(3):279-286.
[45]Li F,Maskey R P,Qin S,et al.CH1N1komycins A and B:isolation,structure elucidation,and biological activity of novel antibiotics from a marine Streptomyces sp.isolate M045[J].J Nat Prod,2005,68(3):349-353.
[46]Maskey RP,Helmke E,KayserO,et al.Anti-cancer and antibacterial trioxacarcins with high anti-malaria activity from a marine Streptomycete and their absolute stereochemistry[J].J Antibiot(Tokyo),2004,57(12):771-779.
[47]XiongL,Li J,KongF.Streptomyces sp.173,an insecticidal microorganism from marine[J].Lett Appl Microbiol,2004,38(1):32-37.
[48]潘云娣,杨文鸽,候温甫,等.产杀虫活性物质海洋放线菌的筛选和初步鉴定[J].海洋通报,2006,25(4):92-96.
[49]刘妍,李志勇.具有多重酶活性的澳大利亚厚皮海绵共附生放线菌的研究[J].生物技术通报,2006,5:121-125.
[50]Imada C.Enzyme inhibitors and other bioactive compounds from marine actinomycetes[J].Antonie Van Leeuwenhoek,2005,87(1):59-63.
[51]赵俊凌,古静燕,候大斌,等.海洋放线菌抗肿瘤活性物质研究进展[J].海洋通报,2007,26(2):91-94.
[52]Bull AT,Stach J E,Ward A C,et al.Marine actinobacteria:perspectives,challenges,future directions[J].Antonie Van Leeuwenhoek,2005,87(3):65-79.
[53]Mincer TJ,Jensen PR,Kauffman CA,et al.Widespread and persistent populations of a major new marine actinomycete taxon in ocean sediments[J].Appl Environ Microbiol,2002,68(10):5005-5011.
[54]Sabry SA,Ghanem NB,Abu-Ella GA,et al.Noeardiopsis aegyptia sp.nov.,isolated from marine sediment[J].Int J Syst Evol Microbiol,2004,54(2):453-456.
[55]Magarvey NA,Keller JM,Beman V,et al.Isolation and characterization of novel marine-derived actinomycete taxa rich in bioactive metabolites[J].Appl Environ Microbiol,2004,70(12):7520-7529.
[56]Pathom-Aree W,Staeh J E,Ward AC,et al.Diversity of actinomycetes isolated from Challenger Deep sediment(10,898 m) from the Mariana Trench[J].Extremophiles,2006,10(3):181-189.
[57]姜健,范圣第,杨宝灵,等.海洋动植物共附生微生物的分离和抗菌活性研究[J].微生物学通报,2005,32(2):65-68.
[58]刘丽,胡江春,王书锦.繁茂膜海绵中两株放线菌的生物学特性及其鉴定[J].氨基酸和生物资源,2004,26(1):1-4.
[59]Zhang H,Lee YK,Zhang W,et al.Culturable actinobacteria from the marine sponge Hymeniacidon perleve:isolation and phylogenetic diversity by 16S rRNA gene-RFLP analysis[J].Antonie Van Leeuwenhoek,2006,90(2):159-169.
[60]Piel J,Hui D,Wen G,et al.Antitumor polyketide biosynthesis by an uncultivated bacterial symbiont of the marine sponge Theonella swinhoei[J].Proc Natl Acad Sci USA.2004,101(46):16222-16227.
[61]Hentschel U,Hopke J,Horn M,et al.Molecular evidence for a uniform microbial community in sponges from different oceans[J].Appl Environ Microbiol,2002,68(9):4431-4440.
[62]Kwon H C,Kauffman C A,Jensen P R,et al.Marinomycins A-D,antitumor-antibiotics of a new structure class from a marine actinomycete of the recently discovered genus "marinispora"[J].J Am Chem Soc,2006,128(5):1622-1632.
[63]Mincer T J,Fenical W,Jensen P R.Culture-dependent and culture-independent diversity within the obligate marine actinomycete genus Salinispora[J].Appl Environ Microbiol, 2005,71(11):7019-7028.
[64]Oh D C,Williams P G,Kauffman C A,et al.Cyanosporasides A and B,chloro-and cyano-cyclopenta[a]indene glycosides from the marine actinomycete "Salinispora pacifica"[J].Org Lett,2006,8(6):1021-1024.
[65]Kim T K,Hewavitharana A K,Shaw P N,et al.Discovery of a new source of rifamycin antibiotics in marine sponge actinobacteria by phylogenetic prediction[J].Appl Environ Microbiol,2006,72(3):2118-2125.
[66]Heald S C,Brandao P F,Hardiere R,et al.Physiology,biochemistry and taxonomy of deep-sea nitrile metabolising Rhodococcus strains[J].Antonie Van Leeuwenhoek,2001,80(2):169-183.
[67]Bruns A,Philipp H,Cypionka H,et al.Aeromicrobium marinum sp.nov.,an abundant pelagic bacterium isolated from the German Wadden Sea[J].Int J Syst Evol Microbiol,2003,53(Pt 6):1917-1923.
[68]Han S K,Nadashkovskaya O I,Mikhailov VV,et al.Salinibacterium amurskyense gen.nov.,sp.nov.,a novel genus of the family Microbacteriaceae from the marine environment[J].Int J Syst Evol Microbiol,2003,53(Pt 6):2061-2066.
[69]Fiedler HP,Bruntner C,Bull AT,et al.Marine actinomycetes as a source of novel secondary metabolites[J].Antonie Van Leeuwenhoek,2005,87(1):37-42.
[70]Jose M,Lopez S,Jensen PR,et al.New Cytotoxic Indolic Metabolites from a Marine Streptomyces[J].J Nat Prod,2003,66:863-864.
[71]王健,崔承彬,顾谦群,等.海洋来源黄直丝链霉菌产物中新细胞周期抑制剂的研究[J].中国海洋药物杂志,2005,24(4):1-5.
[72]Fenical W,Jensen PR.Developing a new resource for drug discovery:marine actinomycete bacteria[J].Nature Chemical Biology,2006,2(12):666-673.
[73]Fururnai T,Iqarashi Y.Kosinostatin,a quinocycline antibiotic with antitumor activity from Micromonosporasp.TP-A0468[J].Antibiotics,2002,55(2):128-133.
[74]Charan RD,Schlingmann G,Janso J,et al.Diazepinomicin,a new antimierobial alkaloid from marine Micromonospora sp.[J].J Nat Prod,2004,67(8):1431-1433.
[75]Maldonado LA,Fenical W,Jensen PR,et al.Salinispora arenicolagen nov,sp nov andSalinispora tropicasp nov,obligate marine actinomycetes belonging to the family Micromonosporaceae[J].Int J Syst Evol Microbiol,2005,55(pt 5):1759-1766.
[76]程元荣,郑卫.小单孢菌及其产生的次级生物活性代谢产物[J].中国抗生素杂志,2006,31(6):321-327.
[77]江红,林如,郑卫,等.海洋青铜小单孢菌FIM 02-523产生的脂肽类化合物FW523的分离鉴别和生物学活性[J].中国抗生素杂志,2006,31(5):267-271.
[78]Lik T,Brian LM,William HG;Lyngbouilloside,a Novel Glycosidic Macrolide from the Marine Cyanobacterium Lyngbya bouillonii[J].J Nat Prod,2002,65(6):925-928.
[79]Hanshan W,Su L,Jun X,et al.Isolation of Streptonigrin and Its Novel Derivative from Micromonospora as Inducing Agents of p53-Dependent Cell Apoptosis[J].J Nat Prod,2002,65(5):721-724.
[80]刘睿,朱天骄,朱伟明,等.海洋放线菌S1001中抗肿瘤活性成分的研究[J].中国抗生素杂志,2006,31(1):36-38.
[81]刘妍,李志勇.海洋放线菌研究的新进展[J].生物技术通报.2005,6:34-39.
[82]Ho-shik K,Rhim H,Jenong SW,etal.Induction of apoptosis dependent on caspase activities and growth arrest in HL-60 cells by PGA2[J].Prostaglandins Other Lipid Mediat,2002,70(1):169-183.
[83]曾益新.肿瘤学[M].北京:人民卫生出版社.2003,83-85,109-110,151-176,209-224.
[84]周彩虹,黄启福.凋亡与肿瘤及其治疗进展[J].中国病理生理杂志,2004,20(11):2124-2133.
[85]Damia G,Broggini M.Improving the selectivity of cancer treatments by interfering with cell response pathways[J].Eur J Cancer,2004,40(17):2550-2559.
[86]Muckelbauer JK,Kremer M,Minor I,et al.The structure of coxsackievirus B3 at 3.5 A resolution[J].Structure.1995,3(7):653-667.
[87]Carson SD,Receptor for the group B coxsackieviruses and adenoviruses:CAR[J].Rev Med Virol,2001,11(4):219-226.
[88]Javett SN,Heymarm S,Mundel B,et al.Myocarditis in the new newborn infant;a study of an outbreak associated with Coxsackie group B virus infection in maternity home in Johannesburg[J].J Pediatr,1956,48(1):1-22.
[89]Saijets S,Ylipaasto P,Vaarala O,et al.Enterovirus infection and activation of human umbilical vein endothelial cells[J].J Med Virol,2003,70(3):430-439.
[90]Storz P,Toker A.NF-κB signaling-an alternate pathway for oxidative stress responses [J].Cell Cycle.2003,2(1):9-10.
[91]Shao J,Fujiwara a,Kadowaki Y,et al.Overexpression of the wild-typep53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells[J].Oncogene.2000,19(6):726-736.
[92]Sarkar FH,Li Y.NF-kappaB:a potential target for cancer chemoprevention and therapy[J].Front Biosci.2008,13:2950-2959.
[93]Van Waes C.Nuclear factor-kappaB in development,prevention,and therapy of cancer[J].Clin Cancer Res.2007,13(4):1076-1082.